Drug Approval | May 30, 2024
Alembic Pharmaceuticals receives USFDA final approval for Sacubitril and Valsartan Tablets
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Subscribe To Our Newsletter & Stay Updated
